Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.60 |
| ▸ | CDK2 | P24941 | 12/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13885182 | 0.90 | GSK3B (0.58) | GSK3BCDK2CDK1CHEK1CCNA2 | |
| SCHEMBL13885183 | 0.89 | CHEK1 (0.56) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL13885152 | 0.85 | CDK2 (0.67) | GSK3BCDK2CDK1CHEK1CCNE1 | |
| SCHEMBL13885062 | 0.80 | GSK3B (0.71) | GSK3BCDK2CDK1CCNE2CCNE1 | |
| SCHEMBL14541404 | 0.80 | GSK3B (0.65) | GSK3BCDK2CDK1MAPKAPK2 | |
| SCHEMBL14541541 | 0.80 | GSK3B (0.60) | GSK3BCDK2CDK1PIK3CAPRKDC | |
| SCHEMBL13885055 | 0.80 | GSK3B (0.51) | GSK3BCDK2 | |
| SCHEMBL13885057 | 0.79 | GSK3B (0.49) | GSK3BCDK2CHEK1 | |
| SCHEMBL13885701 | 0.79 | CHEK1 (0.54) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL13998535 | 0.78 | GSK3B (0.70) | GSK3BCDK2CHEK1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514442-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1534712-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007044420-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7205308-B2 | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205308-B2 | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |